1
|
Almeter PJ, Isaacs JT, Hunter AN, Lyman TA, Zapata SP, Henderson BS, Larkin SA, Long LM, Bossle MN, Bhaktawara SA, Warren MF, Lozier AM, Melson JD, Fraley SR, Relucio EHL, Felix MA, Reynolds JW, Naseman RW, Platt TL, Lodder RA. Screening for quality with process analytical technology in a health-system pharmacy: A primer. Am J Health Syst Pharm 2024; 81:e73-e82. [PMID: 37756628 DOI: 10.1093/ajhp/zxad239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2023] [Indexed: 09/29/2023] Open
Abstract
PURPOSE The University of Kentucky Drug Quality Study team briefly reviews the growing concerns over pharmaceutical manufacturing quality in the globalized environment, reviews the historical approach by the US Food and Drug Administration (FDA) that prioritizes process over product in enforcing quality with manufacturers, reviews the science of process analytical technology (PAT) such as near-infrared (NIR) spectroscopy, illustrates the use of PAT methods for assessing uniformity and quality in injectable pharmaceuticals, and demonstrates the application of NIR spectroscopy in a health-system pharmacy setting while maintaining current good practice quality guidelines and regulations (cGxP). SUMMARY Given that the current approach to monitoring quality in pharmaceutical manufacturing was developed in the late 1960s at a time when manufacturing was mostly domestic, the current approach prioritizes process over product, and the global footprint of manufacturing is straining federal resources to fulfill their task of monitoring quality, an approach to augment the quality monitoring process has been developed. PAT methodologies are supported by FDA for monitoring quality and offer a fast, low-cost, nondestructive solution. Given that the Accreditation Council for Pharmacy Education has not required qualitative/quantitative analysis and drug assaying in the pharmacy curriculum for several decades, the authors spend time explaining the science behind one of these PAT methodologies, NIR spectroscopy. This primer reviews the application of this technology in the health-system pharmacy setting and the relevant clinical applications. CONCLUSION Utilizing PAT methodologies such as NIR spectroscopy, health-system pharmacies can gain insights about whether process controls are in place or lacking in FDA-approved formulations.
Collapse
Affiliation(s)
- Philip J Almeter
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY, USA
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, USA
| | - James T Isaacs
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY, USA
| | - Aaron N Hunter
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY, USA
| | - Thomas A Lyman
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY, USA
| | - Stephanie P Zapata
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY, USA
| | - Bradley S Henderson
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY, USA
| | - Seth A Larkin
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY, USA
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, USA
| | - Lindsey M Long
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY, USA
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, USA
| | - Megan N Bossle
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY, USA
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, USA
| | - Smaran A Bhaktawara
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY, USA
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, USA
| | - Matthew F Warren
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY, USA
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, USA
| | - Austin M Lozier
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY, USA
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, USA
| | - Joshua D Melson
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY, USA
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, USA
| | - Savannah R Fraley
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY, USA
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, USA
| | - Eunice Hazzel L Relucio
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY, USA
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, USA
| | - Margaret A Felix
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY, USA
| | - Jeffrey W Reynolds
- Department of Finance, University of Kentucky HealthCare, Lexington, KY, USA
| | - Ryan W Naseman
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY, USA
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, USA
| | - Thomas L Platt
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY, USA
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, USA
| | - Robert A Lodder
- Pharmaceutical Sciences Department, College of Pharmacy, University of Kentucky, Lexington, KY, USA
| |
Collapse
|
2
|
Isaacs JT, Almeter PJ, Henderson BS, Hunter AN, Platt TL, Lodder RA. Spectrometric Assessment of Generic and Brand Drug Quality for a Sentinel Screening Network. Appl Spectrosc 2023; 77:915-927. [PMID: 37475201 DOI: 10.1177/00037028231184478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/22/2023]
Abstract
The U.S. Food and Drug Administration (FDA) is a worldwide leader among analogous regulatory organizations in other countries. The FDA uses current good manufacturing practices to regulate the processes that produce drugs. Nevertheless, investigative journalists have pointed out problems in the drug supply, and pharmacies are not required to test the drugs they receive. The University of Kentucky Drug Quality Study does perform screening on the sterile injectable drugs that it receives and regularly reports new findings to FDA, practitioners, and the public. A Sentinel Screening Network of academic health systems could provide independent data on drug quality to FDA not available through manufacturers.
Collapse
Affiliation(s)
- James T Isaacs
- Department of Pharmacy Services, University of Kentucky, Lexington, Kentucky, USA
| | - Philip J Almeter
- Department of Pharmacy Services, University of Kentucky, Lexington, Kentucky, USA
- Pharmacy Practice and Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA
| | - Bradley S Henderson
- Department of Pharmacy Services, University of Kentucky, Lexington, Kentucky, USA
| | - Aaron N Hunter
- Department of Pharmacy Services, University of Kentucky, Lexington, Kentucky, USA
| | - Thomas L Platt
- Department of Pharmacy Services, University of Kentucky, Lexington, Kentucky, USA
| | - Robert A Lodder
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky, USA
| |
Collapse
|
3
|
Felix M, Isaacs JT, Almeter PJ, Henderson BS, Hunter AN, Platt TL, Lodder RA. Variability in Content of Hydrocortisone Sodium Succinate. Contact Context 2023; 2023:10.6084/m9.figshare.23573532. [PMID: 37600448 PMCID: PMC10437148 DOI: 10.6084/m9.figshare.23573532] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 08/22/2023]
Abstract
SOLU-CORTEFⓇ Sterile Powder is a type of anti-inflammatory glucocorticoid that contains hydrocortisone sodium succinate as its active ingredient. It can be administered intravenously or intramuscularly, and comes in several packages including 100 mg plain vials without diluent. The diluent, which is part of the ACT-O-VIAL system, contains only Water for Injection and no preservatives. The pH of each formula is adjusted with sodium hydroxide to ensure it falls within the specified range of 7 to 8 after reconstitution. Intralot variability was detected in lot GA6092. Measuring in the PC subspace using just PCs 4, 5 and 6, vial 12 plots 4.2 BEST SDs from the center of the cluster, and vial 7 is 3.7 SDs from the center. Vial 18 appears 3.1 SDS from the center of the cluster (3/18, 17%). Interlot variability was also found in the spectral library (lots GA6092, GK7048, GM6839, GR8925, FL8062, FN6860, FR1914, and FR5098) containing the spectra of 126 hydrocortisone sodium succinate vials.
Collapse
Affiliation(s)
- Margaret Felix
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - James T. Isaacs
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Philip J. Almeter
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40506
| | | | - Aaron N. Hunter
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Thomas L. Platt
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Robert A. Lodder
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536
| |
Collapse
|
4
|
Isaacs JT, Almeter PJ, Henderson BS, Hunter AN, Platt TL, Samano-Garcia C, Lodder RA. Quality Variations in Thyrotropin Alfa. Contact Context 2023; 2023:10.6084/m9.figshare.23524530. [PMID: 37396298 PMCID: PMC10312997 DOI: 10.6084/m9.figshare.23524530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 07/04/2023]
Abstract
Thyrotropin alfa is a heterodimeric glycoprotein containing human thyroid stimulating hormone (TSH). It is used as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer who have previously undergone thyroidectomy. Inter-lot variability in the Fourier transform near-infrared spectra of 30 samples obtained from four separate lots of Thyrogen® was detected in the Drug Quality Study (DQS). The vials fell into two distinct groups (rtst = 0.90, rlim= 0.98, p=0.02). In addition, one vial of the 30 (3%) appeared 4.7 multidimensional SDs from all of the other vials, suggesting that it also represents a different material.
Collapse
Affiliation(s)
- James T. Isaacs
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Philip J. Almeter
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40506
| | | | - Aaron N. Hunter
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Thomas L. Platt
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | | | - Robert A. Lodder
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536
| |
Collapse
|
5
|
Isaacs JT, Almeter PJ, Henderson BS, Hunter AN, Platt TL, McGuire C, Lodder RA. Spectrometric Analysis of Dantrolene Sodium. Contact Context 2023; 2023:10.6084/m9.figshare.23317136. [PMID: 37424832 PMCID: PMC10327630 DOI: 10.6084/m9.figshare.23317136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 07/11/2023]
Abstract
Dantrolene sodium is a direct-acting skeletal muscle relaxant. Dantrolene sodium for injection is indicated, along with suitable supportive measures, for the management of sudden, severe hypermetabolism of skeletal muscle typical of malignant hyperthermia crises in patients of any age. The formulation scanned in this work was designed to be injected intravenously. Intra-lot and inter-lot variability in the spectra of REVONTO™ (dantrolene sodium) was measured in the Drug Quality Study (DQS) using Fourier transform near-infrared spectrometry (FTNIR). Spectra of 69 vials from lot 20REV01A contained two groups (n1=56 vials, n2=13 vials) when scanned with an FTNIR. The two groups of spectra in lot 20REV01A were found to be 66.7 SDs apart using a subcluster detection test, suggesting that the two groups were manufactured differently. As a result, all available samples of dantrolene were examined. A library of spectra of 141 vials of dantrolene from 4 lots were found to contain 3 separate groups, also suggesting that different vials contain different materials.
Collapse
Affiliation(s)
- James T. Isaacs
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Philip J. Almeter
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40506
| | | | - Aaron N. Hunter
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Thomas L. Platt
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Claire McGuire
- Department of Chemistry, University of Kentucky, Lexington, KY 40506
| | - Robert A. Lodder
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536
| |
Collapse
|
6
|
Isaacs JT, Almeter PJ, Hunter AN, Lyman TA, Zapata SP, Henderson BS, Larkin SA, Long LM, Bossle MN, Bhaktawara SA, Warren MF, Lozier AM, Melson JD, Fraley SR, Relucio EHL, Felix MA, Reynolds JW, Naseman RW, Platt TL, Lodder RA. Assessment of Vecuronium Quality Using Near-Infrared Spectrometry. Contact Context 2023; 2023:10.6084/m9.figshare.24846285. [PMID: 38187821 PMCID: PMC10768930 DOI: 10.6084/m9.figshare.24846285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 01/09/2024]
Abstract
This study employed Fourier Transform near-infrared spectrometry to assess the quality of vecuronium bromide, a neuromuscular blocking agent. Spectral data from two lots of vecuronium were collected and analyzed using the BEST metric, principal component analysis (PCA) and other statistical techniques. The results showed that there was variability between the two lots and within each lot. Several outliers in the spectral data suggested potential differences in the chemical composition or sample condition of the vials. The outliers were identified and their spectral features were examined. A total of eight unique outliers were found in the PC space from PCs 1 to 9, so 22% of the total vials were outliers. The study findings suggest that the manufacturing process of vecuronium bromide may have been operating outside of a state of process control. Further investigation is needed to determine the source of these variations and their impact on the safety and efficacy of the drug product.
Collapse
Affiliation(s)
- James T. Isaacs
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536
| | - Philip J. Almeter
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536
| | - Aaron N. Hunter
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536
| | - Thomas A. Lyman
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536
| | - Stephanie P. Zapata
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536
| | - Bradley S. Henderson
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536
| | - Seth A. Larkin
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536
| | - Lindsey M. Long
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536
| | - Megan N. Bossle
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536
| | - Smaran A. Bhaktawara
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536
| | - Matthew F. Warren
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536
| | - Austin M. Lozier
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536
| | - Joshua D. Melson
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536
| | - Savannah R. Fraley
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536
| | - Eunice Hazzel L. Relucio
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536
| | - Margaret A. Felix
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536
| | | | - Ryan W. Naseman
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536
| | - Thomas L. Platt
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536
| | - Robert A. Lodder
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536
| |
Collapse
|
7
|
Isaacs JT, Almeter PJ, Henderson BS, Hunter AN, Platt TL, Anwar H, Lodder RA. Spectral Intra-Lot and Inter-Lot Variability in Carfilzomib. Contact Context 2023; 2023:10.6084/m9.figshare.21971213. [PMID: 37008539 PMCID: PMC10062383 DOI: 10.6084/m9.figshare.21971213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
Abstract
Carfilzomib is a prescription injectable drug approved for use by the FDA as an antineoplastic agent, part of a drug class of medications known as proteasome inhibitors, and used to stop and slow the growth and progression of cancer cells within the body. The drug is approved as an agent to treat multiple myeloma. It is provided as a single-use vial that contains 60 mg of carfilzomib as a sterile, white to off-white lyophilized cake or powder. Intra-lot and inter-lot variability in the spectra of carfilzomib vials was detected in the Drug Quality Study (DQS) using Fourier transform near-infrared spectrometry (FTNIR). One of 12 vials of lot 1143966 manufactured for Onyx Pharmaceuticals, Inc. appeared 4.7 multidimensional standard deviations (SDs) from the other 11 vials in a 3-D space formed by the first 3 principal components, which captured 81% of the total spectral variation. Spectra of 168 vials from 18 lots in the spectral library formed two groups in the 3-D space formed by the first 3 principal components. One group contained 155 vials and the other group contained 13 vials. The 2 groups had different locations and scales using a subcluster detection test at p=0.02.
Collapse
Affiliation(s)
- James T. Isaacs
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Philip J. Almeter
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40506
| | | | - Aaron N. Hunter
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Thomas L. Platt
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Humza Anwar
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536
| | - Robert A. Lodder
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536
- Author to whom correspondence should be addressed.
| |
Collapse
|
8
|
Isaacs JT, Almeter PJ, Henderson BS, Hunter AN, Platt TL, Lodder RA. Spectrometric Analysis of Process Variations in Remifentanil. Contact Context 2022; 2022:10.6084/m9.figshare.21109093. [PMID: 36187755 PMCID: PMC9520611 DOI: 10.6084/m9.figshare.21109093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
ULTIVA® (remifentanil hydrochloride) is a sterile, nonpyrogenic, preservative-free, white to off-white lyophilized powder for intravenous (IV) administration after reconstitution and dilution. Each vial contains 1, 2, or 5 mg of remifentanil base; 15 mg glycine; and hydrochloric acid to buffer the solutions to a nominal pH of 3 after reconstitution. ULTIVA® is a μ-opioid agonist with rapid onset and peak effect, and short duration of action. Intra-lot and inter-lot variability in the spectra of ULTIVA® was measured in the Drug Quality Study (DQS) using Fourier transform near-infrared spectrometry (FTNIR). In 6 vials sampled, 1 came from lot 220453F while 5 came from lot 30020BF. The 1 vial sampled from lot 220453F appeared 122 multidimensional SDs from the other vials from lot 30020BF, suggesting that it represents a different formulation or material. Consequently, additional spectra from other lots were analyzed. Spectra of 90 vials from 9 lots in the spectral library contained vials that were outside the main group (50.3 SDs using a subcluster detection test), suggesting that the 35 library vials (39% of the total) contain different materials from the other 55 vials.
Collapse
Affiliation(s)
- James T. Isaacs
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Philip J. Almeter
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40506
| | | | - Aaron N. Hunter
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Thomas L. Platt
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Robert A. Lodder
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536
| |
Collapse
|
9
|
Isaacs JT, Almeter PJ, Henderson BS, Hunter AN, Platt TL, Lodder RA. Potential Process Control Issues with Pemetrexed. Contact Context 2022; 2022:10.6084/m9.figshare.20245158. [PMID: 35967958 PMCID: PMC9367643 DOI: 10.6084/m9.figshare.20245158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Pemetrexed is a folate analog metabolic inhibitor used in treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer and for mesothelioma. Intra-lot and inter-lot variability in the spectra of ALIMTA® was detected in the Drug Quality Study (DQS) using Fourier transform near-infrared spectrometry (FTNIR). One vial of 12 (8%) sampled from lot S20I013A appeared 3.0 multidimensional SDs from the other vials, suggesting that it represents a different material. Consequently, additional spectra from other lots were analyzed. Spectra of 147 vials from 23 lots in the spectral library contained 14 vials that were outside the main group (26.4 SDs using a subcluster detection test), suggesting that the 14 library vials (9.5% of the total) also contain differing materials.
Collapse
Affiliation(s)
- James T. Isaacs
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Philip J. Almeter
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
- Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40506
| | | | - Aaron N. Hunter
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Thomas L. Platt
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Robert A. Lodder
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536
| |
Collapse
|
10
|
Isaacs JT, Almeter PJ, Henderson BS, Hunter AN, Platt TL, Lodder RA. Variability in Content of Piperacillin and Tazobactam Injection. Contact Context 2022; 2022. [PMID: 35506061 DOI: 10.6084/m9.figshare.19561333] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Piperacillin and Tazobactam Injection is a combination product consisting of a penicillin-class antibacterial, piperacillin, and a beta-lactamase inhibitor, tazobactam, indicated for the treatment of patients with moderate to severe infections caused by susceptible isolates of bacteria. In the past decade some quality problems have been noted by the US Food and Drug Administration (FDA) with the Apotex Corp. manufacturing. Intra-lot and inter-lot variability in the spectra of Piperacillin and Tazobactam Injection 3.375 g was detected in the Drug Quality Study (DQS) using Fourier transform near-infrared spectrometry (FTNIR). One vial of 6 (17%) sampled from lot AD103008F3 appeared 14.4 multidimensional SDs from the other vials, suggesting that it represents a different material. Spectra of 132 vials from 19 lots in the spectral library contained 4 vials that were outside the group (21.0 SDs using a subcluster detection test), suggesting that the 4 library vials (3%) also contain differing materials.
Collapse
Affiliation(s)
- James T Isaacs
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Philip J Almeter
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536.,Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40506
| | - Bradley S Henderson
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Aaron N Hunter
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Thomas L Platt
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Robert A Lodder
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536
| |
Collapse
|
11
|
Isaacs JT, Almeter PJ, Henderson BS, Hunter AN, Platt TL, Lodder RA. Levothyroxine Variations by Process Analytical Technology. Contact Context 2022; 2022. [PMID: 35440917 DOI: 10.6084/m9.figshare.18316523] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Intra-lot and inter-lot variability in the spectra of levothyroxine was detected in the Drug Quality Study (DQS) using Fourier transform near-infrared spectrometry (FTNIR). Two vials of 12 vials sampled from Athenex lot AFN102 appeared 10.1 and 9.1 SDs from the center of the rest of the vials on the DQS FTNIR screening assay. Spectra of 108 vials from six lots in the library clustered in two groups (p=0.02), suggesting they represent different material.
Collapse
|
12
|
Abstract
The measles, mumps, and rubella (MMR) vaccine is a vaccine used to prevent measles, mumps, and rubella (German measles). The vaccine is mandated for children to attend public school in nearly all US states. However, measles cases have been increasing in the past decade, and quality problems have recently been noted by the US Food and Drug Administration (FDA) with the vaccine manufacturer. Intra-lot and inter-lot variability in the spectra of MMR (measles, mumps, and rubella) vaccine was detected in the Drug Quality Study (DQS) using Fourier transform near-infrared spectrometry (FTNIR). Six vials of 12 (50%) sampled from Merck lot U006488 appeared 14.5 SDs from the other vials on a subcluster detection test, suggesting that they represent different material. Spectra of 198 vials from 12 lots in the spectral library contained 140 vials in one tight ellipsoidal group, and 58 vials (30%) were outside that group (39.7 SDs using a subcluster detection test), suggesting that the library vials also contain differing materials.
Collapse
Affiliation(s)
- James T Isaacs
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Philip J Almeter
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536.,Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40506
| | - Bradley S Henderson
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Aaron N Hunter
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Thomas L Platt
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Robert A Lodder
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536
| |
Collapse
|
13
|
Isaacs JT, Almeter PJ, Henderson BS, Hunter AN, Platt TL, Lodder RA. FTNIR Spectrometry of Micafungin Sodium Quality. Contact Context 2022; 2022. [PMID: 35360460 DOI: 10.6084/m9.figshare.19071704] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Intra-lot and inter-lot variability in the spectra of micafungin was detected in the Drug Quality Study (DQS) using Fourier transform near-infrared spectrometry (FTNIR). Two vials of 6 vials sampled from Fresenius Kabi lot ACP106 appeared 7.9 and 14.0 standard deviations (SDs) from the center of the rest of the vials on the DQS FTNIR screening assay. Spectra of 48 vials from 7 lots in the library showed 2 outliers at 8.3 and 9.8 SDs from the center of the rest of the library, suggesting they represent different material.
Collapse
Affiliation(s)
- James T Isaacs
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Philip J Almeter
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536.,Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40506
| | - Bradley S Henderson
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Aaron N Hunter
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Thomas L Platt
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Robert A Lodder
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536
| |
Collapse
|
14
|
Isaacs JT, Almeter PJ, Henderson BS, Hunter AN, Platt TL, Lodder RA. Spectrometric Results of Process Variations in Dacarbazine. Contact Context 2022; 2022. [PMID: 35035310 DOI: 10.6084/m9.figshare.17868614] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Intra-lot and inter-lot variability in dacarbazine was detected in the Drug Quality Study (DQS) using Fourier transform near-infrared spectrometry (FTNIR). One vial of six vials sampled from Fresenius Kabi Lot 6125612 appeared 7.8 SDs from the center of the rest of the vials on the DQS FTNIR screening assay. Spectra of 54 vials from six lots in the library clustered in two groups (p=0.02), suggesting they represent different material.
Collapse
Affiliation(s)
- James T Isaacs
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Philip J Almeter
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536.,Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40506
| | - Bradley S Henderson
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Aaron N Hunter
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Thomas L Platt
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Robert A Lodder
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536
| |
Collapse
|
15
|
Abstract
Intra-lot and inter-lot variability in cosyntropin was detected in the DQS using Fourier transform near-infrared spectrometry. One vial of 12 sampled from Sandoz Lot0200062 appeared 6.9 SDs from the center of the rest of the vials, and another was 4.3 SDs away. Spectra of 102 vials from 7 lots in the library clustered in two groups (p=0.02).
Collapse
Affiliation(s)
- Philip J Almeter
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536.,Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40506
| | - James T Isaacs
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Aaron N Hunter
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Bradley S Henderson
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Robert A Lodder
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536
| |
Collapse
|
16
|
Almeter PJ, Butler WR, Reynolds JW, Duckworth DL, Labuhn JA, Birdwhistell MD. Pharmacy benefit manager reform within Medicaid Managed Care: The pursuit of a model that preserves the intent of the 340B program. Am J Health Syst Pharm 2022; 79:1607-1611. [PMID: 35020794 DOI: 10.1093/ajhp/zxac012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.
Collapse
Affiliation(s)
- Philip J Almeter
- Department of Pharmacy, University of Kentucky HealthCare, Lexington, KY, and Pharmacy Practice & Science Department, University of Kentucky College of Pharmacy, Lexington, KY, USA
| | | | - Jeffrey W Reynolds
- Department of Finance, University of Kentucky HealthCare, Lexington, KY, USA
| | - Deborah L Duckworth
- Department of Pharmacy, University of Kentucky HealthCare, Lexington, KY, USA
| | - Jonathan A Labuhn
- Department of Pharmacy, University of Kentucky HealthCare, Lexington, KY, and Pharmacy Practice & Science Department, University of Kentucky College of Pharmacy, Lexington, KY, USA
| | - Mark D Birdwhistell
- Office of the Executive Vice President for Health Affairs, University of Kentucky HealthCare, Lexington, KY, and Clinical Leadership and Management Department, University of Kentucky College of Health Sciences, Lexington, KY, USA
| |
Collapse
|
17
|
Almeter PJ, Isaacs JT, Schuler EE, Lodder RA. Potential Process Control Issues with Remdesivir. Contact Context 2021; 2021:10.6084/m9.figshare.16417218. [PMID: 34924886 PMCID: PMC8679181 DOI: 10.6084/m9.figshare.16417218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Affiliation(s)
- Philip J. Almeter
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536,Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40506
| | - James T. Isaacs
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Erin E. Schuler
- Pathology & Laboratory Medicine, College of Medicine, University of Kentucky, Lexington, KY 40536
| | - Robert A. Lodder
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536,Author to whom correspondence should be addressed.
| |
Collapse
|
18
|
Almeter PJ, Isaacs JT, Hunter AN, Henderson BS, Lodder RA. Intra-Lot and Inter-Lot Variability in Ceftaroline Fosamil. Contact Context 2021; 2021. [PMID: 35360663 DOI: 10.6084/m9.figshare.17292596] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Intra-lot and inter-lot variability in ceftaroline fosamil was detected in the DQS using Fourier transform near-infrared spectrometry. One vial of 18 sampled from Lot0013E06 appeared 9.0 SDs from the center of the rest of the vials. Six lots in the spectral library clustered in two large groups.
Collapse
Affiliation(s)
- Philip J Almeter
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536.,Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40506
| | - James T Isaacs
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Aaron N Hunter
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Bradley S Henderson
- Department of Pharmacy Services, University of Kentucky, Lexington, KY 40536
| | - Robert A Lodder
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536
| |
Collapse
|
19
|
Almeter PJ, Hessel EA, Labuhn JA, Morris PE. Editorial by US Food and Drug Administration Attorney Fails to Address Core and Ongoing Issues Seen With Vasopressin Market. Anesth Analg 2019; 128:e55-e56. [PMID: 30730466 DOI: 10.1213/ane.0000000000004042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Philip J Almeter
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, Kentucky Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, Kentucky, Department of Anesthesiology, University of Kentucky College of Medicine, Lexington, Kentucky Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, Kentucky Division of Pulmonary, Critical Care and Sleep Medicine, University of Kentucky College of Medicine, Lexington, Kentucky
| | | | | | | |
Collapse
|
20
|
Abstract
BACKGROUND The purpose of the US Food and Drug Administration's Marketed Unapproved Drugs Initiative is to decrease marketing of older unapproved medications. The administration has recently extended its rulings by including sterile injectable drugs administered in the inpatient environment. The impact of this initiative on the inpatient environment has been minimally studied. METHODS Consecutive retrospective purchase data of vasopressin for injection (vasopressin) and neostigmine methylsulfate for injection (neostigmine) from 720 hospitals and 746 hospitals, respectively, were included. Purchases occurred from January 1, 2010 to December 31, 2016. The average noncontract drug price was calculated and compared to the purchase data during the impact of the initiative. Comparison was made of hospital purchases made before and after the initiative. The year 2014 was considered a washout transition year due to the large amounts of discontinued unapproved formulations that were still available and purchased by hospitals. The analysis was completed using a matched paired t test. RESULTS The noncontract price for vasopressin increased from $12.83 per vial to $158.83 per vial (1138% increase) and for neostigmine from $27.74 per vial to $175.14 per vial (531% increase) across the pre- and postinitiative intervals; however, purchase volumes after the price increases were not found to have a statistically significant difference compared to purchases before the price increases (P = .98 and P = .4, respectively). CONCLUSIONS Health systems have experienced a significant cost increase of vasopressin and neostigmine and are absorbing price increases for these older, generic sterile injectable drugs.
Collapse
Affiliation(s)
- Philip J Almeter
- From the Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, Kentucky.,Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, Kentucky
| | - Jonathan A Labuhn
- From the Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, Kentucky
| | - Peter E Morris
- Division of Pulmonary, Critical Care and Sleep Medicine, and
| | - Eugene A Hessel
- Department of Anesthesiology, University of Kentucky College of Medicine, Lexington, Kentucky
| |
Collapse
|
21
|
Vermeulen LC, Kolesar J, Crismon ML, Flynn AJ, Stevenson JG, Almeter PJ, Heath WM, Short GT, Enright SM, Ploetz P, Swarthout MD, Zellmer WA, Saenz R, Devereaux DS, Zilz DA, Hoffman JM, Evans WE, Knoer SJ, Ray MD. ASHP Foundation Pharmacy Forecast 2018: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. Am J Health Syst Pharm 2017; 75:23-54. [PMID: 29158305 PMCID: PMC6407484 DOI: 10.2146/sp180001] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Affiliation(s)
- Lee C Vermeulen
- Chief, Academic Service Lines, UK HealthCare, Lexington, KY .,Professor of Medicine and Pharmacy, University of Kentucky, Lexington, KY
| | - Jill Kolesar
- Professor, College of Pharmacy, University of Kentucky, Lexington, KY .,Director, Early Phase Clinical Trials Center, Markey Cancer Center, Lexington, KY
| | - M Lynn Crismon
- Dean, James T. Doluisio Regents Chair and Behrens Centennial Professor, College of Pharmacy, The University of Texas at Austin, Austin, TX
| | - Allen J Flynn
- Research Analyst, Medical School, School of Information, University of Michigan, Ann Arbor, MI
| | - James G Stevenson
- Professor, Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI.,President, Hospital and Health-System Services, Visante, St. Paul, MN
| | - Philip J Almeter
- Director of Pharmacy, UK HealthCare, Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, KY
| | - W Mike Heath
- COL (ret.) U.S. Army, Heath Healthcare Consulting, Lexington, KY
| | - G Tyler Short
- Pharmacy Resident, Department of Pharmacy, UK HealthCare, Lexington, KY
| | | | - Pam Ploetz
- Clinical Associate Professor Emeritus, University of Wisconsin-Madison School of Pharmacy, Madison, WI
| | - Meghan D Swarthout
- Division Director, Ambulatory and Transitions of Care Services, Department of Pharmacy, Johns Hopkins Hospital, Baltimore, MD
| | | | - Rafael Saenz
- Administrator, Pharmacy Services, University of Virginia Health System, Charlottesville, VA
| | - Debra S Devereaux
- Senior Vice President, Pharmacy and Clinical Solutions, Gorman Health Group, Ft. Collins, CO
| | - David A Zilz
- Clinical Professor Emeritus, University of Wisconsin School of Pharmacy, Madison, WI
| | - James M Hoffman
- Chief Patient Safety Officer, Associate Member, Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN
| | - William E Evans
- Chair in Pharmacogenomics, Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN
| | - Scott J Knoer
- Chief Pharmacy Officer, Cleveland Clinic, Cleveland, OH
| | | |
Collapse
|
22
|
Almeter PJ, Johnson GL, Schwieterman PA, Grantz DA, Pasala PP. Ambulatory care pharmacy: Realizing the potential for patient access and operational excellence. Am J Health Syst Pharm 2017. [DOI: 10.2146/ajhp160802] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Affiliation(s)
- Philip J. Almeter
- Department of Pharmacy, University of Kentucky–UK HealthCare, Lexington, KY
| | - Gary L. Johnson
- Department of Pharmacy, University of Kentucky–UK HealthCare, Lexington, KY
| | - Philip A. Schwieterman
- Department of Pharmacy, University of Kentucky–UK HealthCare and Markey Cancer Center, Lexington, KY
| | - Daniel A. Grantz
- Department of Pharmacy, University of Kentucky–UK HealthCare, Lexington, KY
| | - Priya P. Pasala
- Department of Pharmacy, University of Kentucky–UK HealthCare, Lexington, KY
| |
Collapse
|
23
|
Flannery AH, Pandya K, Laine ME, Almeter PJ, Flynn JD. Managing the Rising Costs and High Drug Expenditures in Critical Care Pharmacy Practice. Pharmacotherapy 2016; 37:54-64. [PMID: 27995636 DOI: 10.1002/phar.1862] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Pharmaceutical costs for patients in the intensive care unit (ICU) constitute a large portion of hospital drug budgets. Unfortunately, prices for medications commonly used in the ICU are on the rise for a variety of reasons. In particular, the U.S. Food and Drug Administration's Unapproved Drugs Initiative, generic manufacturers cornering the marketplace, drug shortages, and regulatory device changes are major drivers of pharmaceutical price escalation affecting costs in the ICU. Furthermore, traditional high acquisition cost items still pose challenges to controlling costs. To offer strategies to mitigate the rising costs of pharmaceuticals in the ICU setting, we searched the PubMed/Medline and International Pharmaceutical Abstracts databases and other related sources to identify published cost-saving protocols concerning specific medications that are affected by rising prices or have traditional high acquisition costs. In the absence of specific protocols, we offer possible cost-saving initiatives based on published literature regarding specific agents or based on our own diverse set of experiences. Finally, we review suggested clinical and operational activities at an institutional level to address these rising drug costs in the ICU setting.
Collapse
Affiliation(s)
- Alexander H Flannery
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, Kentucky.,Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, Kentucky
| | - Komal Pandya
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, Kentucky.,Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, Kentucky
| | - Melanie E Laine
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, Kentucky
| | - Philip J Almeter
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, Kentucky
| | - Jeremy D Flynn
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, Kentucky.,Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, Kentucky
| |
Collapse
|
24
|
Almeter PJ, Johnson GL, Saenz R. Optimizing 340B purchasing practices. Am J Health Syst Pharm 2012; 69:1366-8, 1370-1. [DOI: 10.2146/ajhp110626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Affiliation(s)
- Philip J. Almeter
- Department of Pharmacy Services University of Virginia Health System P.O. Box 800674 Charlottesville, VA 22908
| | | | - Rafael Saenz
- Department of Pharmacy Services University of Virginia Health System
| |
Collapse
|